CD4 and neoplasm: Furthermore, ATCT of TH9 cells in advanced B16-OVA melanoma tumor-bearing mice revealed that these cells exert potent effector functions, which are distinct from TH1 and TH17 CD4+ T cell subsets, and express less exhaustion markers (i.e. PD-1 and LAG3).